Aquinox Halts All Rosiptor IC/BPS Research But Continues Chronic Prostatitis Study
We were heartbroken to learn that Rosiptor (AQX-1125), once believed to be a promising new therapy for interstitial cystitis and bladder pain syndrome, has failed to demonstrate success in their latest clinical trial, the Phase 3 LEADERSHIP 301 study. In a press conference, David Main, CEO of Aquinox Pharmaceuticals, said “This is a disappointing result for [...]